Brexucabtagene autoleucel 40million-200million cells/68ml dispersion for infusion bags
NHS hospitals in England used £24,973,322 of indicative cost of Brexucabtagene autoleucel 40million-200million cells/68ml dispersion for infusion bags in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 16.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Brexucabtagene autoleucel 40million-200million cells/68ml dispersion for infusion bags: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Brexucabtagene autoleucel 40million-200million cells/68ml dispersion for infusion bags most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| King's College Hpl Nhs Foundation Trust | £2,528,944 |
| Oxford University Hospitals Nhs Ft | £2,212,826 |
| Imperial College Healthcare Nhs Trust | £2,212,826 |
| University College London Foundation Tr | £1,896,708 |
| Leeds Teaching Hpls Nhs Trust | £1,896,708 |
| Manchester University Nhs Ft | £1,580,590 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,580,590 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,580,590 |
| Univ Hpls Bristol Nhs Foundation Trust | £1,580,590 |
| University Hospital Southampton Nhs Ft | £1,580,590 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.